| ID | 1116 |
| Name of the vaccine | Typhim Vi |
| Microbe | Bacteria |
| Disease name | Typhoid |
| Name of bacteria | Salmonella typhi |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 2 years and older |
| Description of the vaccine | Typhoid Vi polysaccharide vaccine. |
| Name of the manufacturer | Sanofi Pasteur SA |
| Name of the manufacturing country | France |
| Year of manufacture | 2020 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | The protective efficacy was 74% for blood culture confirmed cases of typhoid fever during 20 months of post-vaccination follow-up. |
| Vaccine formulation | Suspension for injection |
| Dosage | Single injection of 0.5 mL. A reimmunizing dose is 0.5 mL. |
| Mechanism of action | Production of IgG antibodies and is T cell independent. |
| Route of administration | Intramuscular |
| Indications | Recommended to travellers for areas like Africa, Asia, and Central and South America. |
| Export | Distributed by - Sanofi Pasteur Inc., USA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Injection site pain, erythema and induration. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | 24599532 |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/75993/download |
| Other name | NA |
| Additional Links | NA
|